nference and Novo Announce Strategic Collaboration to Advance Cardiometabolic Disease Research
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Original GlobeWire Daily editorial illustration — not an event photograph.
nference announced a strategic collaboration with Novo Nordisk to advance research in cardiometabolic disease, including obesity, diabetes, and cardiovascular disease. The partnership aims to combine clinical trial data with artificial intelligence technology and federated healthcare data networks to better understand disease progression and treatment outcomes.
Research Focus and Objectives
- Combining Novo's clinical trial data with nference's AI technology.
- Advancing clinical pharmacology, combination therapies, and precision trials.
- Tracking weight loss alongside whole-body health metrics.
Researchers from both organizations plan to analyze treatment effectiveness, safety, and long-term health outcomes using medical records, diagnostic data, and real-world evidence while maintaining privacy safeguards. Additionally, the initiative includes a parallel framework for venture co-creation to support AI-native companies focused on cardiometabolic health and healthy ageing.
Verification and Practical Implications
Readers and researchers can verify the original announcement through official press release channels on PR Newswire or by visiting the official websites of nference and Novo Nordisk. The collaboration is intended to generate evidence to support the development of future treatments, though specific clinical timelines and deliverables remain subject to ongoing research developments.
AI-assisted reporting; source claims are attributed and have not been independently verified.



